News

Yahoo Finance2y
Mapi Pharma to Host a Key Opinion Leader Webinar on Glatiramer Acetate Depot
NESS ZIONA, Israel, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company focused on introducing innovative long-acting ...
Yahoo Finance2y
Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial for Relapsing forms of Multiple Sclerosis (RMS)
NESS ZIONA, Israel, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company focused on introducing innovative long-acting ...
FierceBiotech10y
Mapi Pharma closes $10M Series A round after two scuttled IPOs
Mapi Pharma has closed a $10 million (€9 million) Series A round to finance mid-phase trials of its once-a-month version of Teva's ($TEVA) blockbuster multiple ...
FiercePharma1y
Viatris' launch plans scuttled as FDA rebuffs long-acting MS drug from partner Mapi
Viatris likely just lost one of its top product debuts for 2024, thanks to an FDA rejection of its partner Mapi Pharma’s application for a new version of Teva’s multiple sclerosis (MS ...